Search research articles
Contact Us
Filters
Showing results (21-30 of 40) with videos related to
Page
of 4
Sort By:
British Journal of Haematology
|
November 27, 2023
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib
Giulio Sartori, Chiara Tarantelli, Filippo Spriano, et al.
European Journal of Medicinal Chemistry
|
December 11, 2022
RS6077 induces mitotic arrest and selectively activates cell death in human cancer cell lines and in a lymphoma tumor in vivo
Jessica Sebastiani, Michela Puxeddu, Marianna Nalli, et al.
Blood Advances
|
September 4, 2020
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
Filippo Spriano, Eugenio Gaudio, Luciano Cascione, et al.
ESMO Open
|
October 12, 2018
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, et al.
Cancer Research Communications
|
April 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
Zoë Johnson, Chiara Tarantelli, Elisa Civanelli, et al.
Molecular Cancer Therapeutics
|
February 7, 2024
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini, et al.
Haematologica
|
February 9, 2019
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W Hicks, Chiara Tarantelli, Alan Wilhem, et al.
Marine Drugs
|
December 9, 2020
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
Marilia Barreca, Virginia Spanò, Alessandra Montalbano, et al.
Blood Advances
|
March 4, 2020
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
Chiara Tarantelli, Martin Lange, Eugenio Gaudio, et al.
Haematologica
|
May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy
Chiara Tarantelli, David Wald, Nicolas Munz, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 40) with videos related to
Sort By:
Page
of 4
British Journal of Haematology
|
November 27, 2023
The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib
Giulio Sartori, Chiara Tarantelli, Filippo Spriano, et al.
European Journal of Medicinal Chemistry
|
December 11, 2022
RS6077 induces mitotic arrest and selectively activates cell death in human cancer cell lines and in a lymphoma tumor in vivo
Jessica Sebastiani, Michela Puxeddu, Marianna Nalli, et al.
Blood Advances
|
September 4, 2020
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
Filippo Spriano, Eugenio Gaudio, Luciano Cascione, et al.
ESMO Open
|
October 12, 2018
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, et al.
Cancer Research Communications
|
April 17, 2023
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
Zoë Johnson, Chiara Tarantelli, Elisa Civanelli, et al.
Molecular Cancer Therapeutics
|
February 7, 2024
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini, et al.
Haematologica
|
February 9, 2019
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W Hicks, Chiara Tarantelli, Alan Wilhem, et al.
Marine Drugs
|
December 9, 2020
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
Marilia Barreca, Virginia Spanò, Alessandra Montalbano, et al.
Blood Advances
|
March 4, 2020
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
Chiara Tarantelli, Martin Lange, Eugenio Gaudio, et al.
Haematologica
|
May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy
Chiara Tarantelli, David Wald, Nicolas Munz, et al.
Page
of 4